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A B S T R A C T   
Malaria, leishmaniasis and trypanosomiasis are arthropod-borne, parasitic diseases that constitute a major global 
health problem. They are generally found in developing countries, where lack of access to preventive tools and 
treatment hinders their management. Because these parasites share an increased demand on glucose consump-
tion with most cancer cells, six compounds used in anti-tumoral research were selected to be tested as anti-
parasitic agents in in vitro models of Leishmania infantum, Trypanosoma brucei, T. cruzi, and Plasmodium 
falciparum: dichloroacetic acid (DCA), 3-bromopyruvic acid (3BP), 2-deoxy-D-glucose (2DG), lonidamine (LND), 
metformin (MET), and sirolimus (SIR). No parasite-killing activity was found in L. infantum promastigotes, 
whereas DCA and 3BP reduced the burden of intra-macrophagic amastigotes. For T. brucei all selected com-
pounds, but 2DG, decreased parasite survival. DCA, 2DG, LND and MET showed parasite-killing activity in T. 
cruzi. Finally, anti-plasmodial activity was found for DCA, 2DG, LND, MET and SIR. These results reinforce the 
hypothesis that drugs with proven efficacy in the treatment of cancer by interfering with ATP production, 
proliferation, and survival cell strategies might be useful in treating threatening parasitic diseases and provide 
new opportunities for their repurposing.   
1. Introduction 
Arthropod-borne parasitic infections are responsible for a number of 
severe diseases found around the world. They include primarily malaria, 
visceral leishmaniasis (VL), and American and African trypanosomiasis 
(Chagas disease and Human African Trypanosomiasis (HAT), also 
known as sleeping sickness, respectively). Malaria is caused by parasites 
belonging to the Plasmodium genus with P. falciparum being the most 
pathogenic for humans. VL, Chagas disease and HAT are brought about 
by Leishmania spp., Trypanosoma cruzi, and T. brucei, respectively, all 
belonging to the Trypanosomatidae family. These diseases are currently 
considered neglected because they mainly affect developing countries 
where there is a lack of access to tools and drugs for prevention and 
treatment. The existence of both wild and domestic reservoirs makes 
controlling the spread of these diseases even more difficult. Despite 
considerable efforts undertaken throughout the last decades, which have 
resulted in a marked decline in their incidence, parasite diseases remain 
a major public health problem. The latest World Health Organization 
(WHO) report shows that these parasites cause diseases in more than 
200 million people annually. In 2018, there were an estimated 228 
million cases of malaria worldwide, around 90,000 people were diag-
nosed with VL, almost 1000 with HAT, and roughly 7 million people 
were estimated to be chronically affected by Chagas disease. For the 
same year, more than 400,000 individuals, many of them children, died 
due to these parasitic infections (World Health Organization, 2020). 
No vaccines have yet been commercialized for humans against these 
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pathogens, thus the main approach for their management is based on 
pharmacological treatment. Developing new drugs involves both large 
budgets and long lead-times. In contrast, drug repurposing is a rapid and 
cheaper alternative because it employs validated molecular targets and 
drugs for new indications. This is especially helpful for neglected dis-
eases since only a small percentage of total investment in health research 
goes to drug discovery for tropical diseases (Nwaka et al., 2009). 
Because of their changing life conditions, these pathogens exhibit 
different metabolic profiles during their biological cycle, which are 
associated with major changes in central carbon metabolism. Of special 
interest is the energetic metabolism that these parasites exhibit within 
the host where they undergo rapid multiplication. 
Bloodstream stages of T. brucei show the simplest metabolism of 
trypanosomatids, where the sole source of ATP is glucose via glycolysis, 
being pyruvate the main end product (Coley et al., 2011). T. cruzi and 
Leishmania spp amastigotes can degrade other metabolites than glucose, 
such as amino acids, and glycolysis is extended to a reversible succinate 
production pathway within the glycosome (Besteiro et al., 2002; Mau-
geri et al., 2011). The resulting pyruvate is transformed into alanine or 
transported to the mitochondrion, instead of being excreted to the 
external milieu. These parasites show a much more complex mito-
chondrial metabolism that is strongly connected to anabolic processes 
and OXPHOS, with a cytochrome-containing respiratory chain (Tielens 
and van Hellemond, 2009). Notwithstanding, the high metabolic de-
mand to support rapid multiplication in the mammalian host, turns 
glycolysis into an essential process for these amastigote-stage trypano-
somatids (Verlinde et al., 2001; Subramanian et al., 2015; Shah-Simpson 
et al., 2017), with special interest for NADPH regeneration and for the 
correct functioning of their PPP (Maugeri et al., 2003, 2011). As it is the 
case for trypanosomatids, P. falciparum intraerythrocytic asexual forms 
are highly dependent on glucose (Sherman, 1998), and preliminary re-
sults indicate that these parasites are aerobic glycolytic organisms with a 
modified TCA mainly fueled by glutamine and glutamate and low 
OXPHOS (Salcedo-Sora et al., 2014). Same as T. brucei bloodstream 
stage, P. falciparum glycolysis products are pyruvate and alanine. 
However, P. falciparum has a functional lactate dehydrogenase which 
transforms some of the generated pyruvate into lactate that is excreted 
to the external milieu (Salcedo-Sora et al., 2014; Penkler et al., 2015). As 
a result, glycolysis appears to be a particularly suitable target to be 
blocked, as these parasites tend to be more dependent on this pathway 
than the quiescent cells from differentiated tissues of their hosts (Renslo 
and McKerrow, 2006). 
Interestingly, an increased glucose consumption and glycolytic ac-
tivity is also a common feature in some studied disease models, as it is 
the case of cancer. Most cancer cell types are known to have an enhanced 
and modified glycolytic metabolism, even in the presence of oxygen 
(aerobic glycolysis), resulting in glucose transformation to lactate 
(Warburg et al., 1924; Warburg, 1956). In addition, there is a reduced 
flux of carbon to the mitochondrion which is highly involved in anabolic 
processes (Vander Heiden et al., 2009). Hence, glycolysis turns into a 
therapeutic target for proliferation-committed cells. 
An imbalance in ATP production —either due to glucose deprivation, 
hypoxia, pharmacological disruptors, such as glycolysis inhibitors, or 
bioenergetic modulators— leads to activation of AMP-activated protein 
kinase (AMPK), an upstream protein of the mechanistic target of rapa-
mycin (mTOR) (Hardie, 2011). As in the case of glycolysis, the mTOR 
route could be also a main therapeutic target for 
proliferation-committed cells, since it acts as a key homeostatic sensor 
that integrates microenvironmental and proliferation signals with bio-
energetic metabolism to regulate biomass production and cell survival 
(Sabatini and Laplante, 2012). Furthermore, the mTOR route is strongly 
related to glycolysis as it is able to regulate the expression of many 
glucose transporters and some glycolysis enzymes through the 
Hypoxia-inducible Factor 1 (HIF-1), thus favoring aerobic glycolysis 
over mitochondrial respiration (Düvel et al., 2010). 
These bioenergetics pathways have been proposed as potential and 
interesting targets for fighting protozoan diseases (Verlinde et al., 2001; 
Jacobs et al., 2011; Saldivia et al., 2013). Likewise, some energy mod-
ulators are already in use in cancer diagnosis, or in advanced phases of 
clinical trials (Scatena et al., 2008; Granchi and Minutolo, 2013), thus 
facilitating repurposing. 
The aim of the present study was to test the hypothesis that drugs 
acting on these metabolic pathways, and whose efficacy in cancer 
research has been demonstrated, could be useful in the management of a 
number of parasitic diseases, including Chagas disease, HAT, VL and 
malaria. The following compounds were selected: 3-bromopyruvic acid 
(3BP), 2-deoxy-D-glucose (2DG), lonidamine (LND), dichloroacetic acid 
(DCA), metformin (MET), and sirolimus (SIR) (Table 1). LND, 3BP, and 
2DG block early stages of the glycolytic route as they interfere with the 
activity of hexokinase (HK) or cannot be further metabolized (Paggi 
et al., 1988). Initially, 3BP was described as inhibiting HKII activity (Ko 
et al., 2001), however, it has been shown to also exhibit inhibitory ac-
tivity on GAPDH, another enzyme of the same pathway (Ganapathy--
Kanniappan et al., 2009). DCA and the biguanide MET were chosen 
because of their ability to modulate ATP and biomass production 
pathways at mitochondrial level. DCA switches cell metabolism from 
aerobic glycolysis to oxidative phosphorylation by restoring mitochon-
drial activity (Michelakis et al., 2008). MET blocks the mitochondrial 
respiratory chain complex I thus provoking unbalanced ATP production 
(Owen et al., 2000) and AMPK activation (Fryer et al., 2002). Finally, 
SIR was included because of its direct inhibiting activity on mTOR (Mita 
et al., 2003). 
2. Material and methods 
To initially assess the aptitude of the known compounds 2-deoxy-D- 
Glucose, 3-bromopyruvic acid, lonidamine, sirolimus, dichloroacetic 
acid and metformin to manage malaria, visceral leishmaniasis, and Af-
rican and American trypanosomiasis, we first studied their associated in 
vitro effect. For that purpose, we tested the cytotoxicity of these com-
pounds to host cells of each in vitro culture model based on cancer 
research literature, determining the range of possible therapeutic con-
centrations. Once established, these compounds were assayed on in vitro 
cultures of L. infantum promastigotes, intra-macrophagic L. infantum 
amastigotes, intra-cellular T. cruzi amastigotes, bloodstream T. brucei 
trypomastigotes, and P. falciparum-infected red blood cells. Parasites 
were co-cultured for 48–72 h with the studied compounds and their 
efficacy was recorded as the ability of each one to reduce the number of 
parasite forms. IC50 values were calculated and compared between 
models and with first-line drugs. Each test was performed three times. 
2.1. Parasites and mammalian cell cultures 
L. infantum JPC strain (MCAN/ES/1998/LLM-724) promastigotes 
were cultured at 26 ◦C in R15 medium [RPMI 1640 medium (Gibco®) 
supplemented with 15% heat-inactivated fetal bovine serum (FBS) 
(Gibco®), 2% HEPES 1M (Gibco®), 1% 10000 U/mL penicillin, and 
Table 1 
Selected drugs and their energetic and biomass production-related targets.  
Compound Energy and biomass production-related target 
3-Bromopyruvic acid GAPDH (Ganapathy-Kanniappan et al., 2009); 
Hexokinase II (Ko et al., 2001) 
2-Deoxy-D-glucose Glycolysis (Nirenberg and Hogg, 1958) 
Lonidamine Hexokinase I (Paggi et al., 1988) 
Sodium dichloroacetate PDK (Michelakis et al., 2008) 
Metformin Complex I of the OXPHOS (Owen et al., 2000); 
AMP-activated protein kinase (Fryer et al., 2002) 
Sirolimus mTOR (Mita et al., 2003) 
Acronyms: GAPDH (glyceraldehyde-3-phosphate dehydrogenase), PDK (pyru-
vate dehydrogenase kinase), OXPHOS (oxidative phosphorylation), AMP 
(adenosine monophosphate), and mTOR (mechanistic target of rapamycin). 
A. Martínez-Flórez et al.                                                                                                                                                                                                                      
International Journal for Parasitology: Drugs and Drug Resistance 14 (2020) 17–27
19
10,000 μg/mL streptomycin (Gibco®)]. Weekly passages were per-
formed. Metacyclic promastigotes for in vitro infections were obtained 
from a 6-day-old stationary culture. U937 human macrophages derived 
from a Caucasian histiocytic lymphoma were obtained from the Euro-
pean Collection of Cell Cultures (ECACC). Cells were cultured in RU937 
media (RPMI-1640 medium supplemented with 10% FBS and 1% 
Penicillin/Streptomycin), and kept in a humid atmosphere at 37 ◦C and 
5% CO2. Before carrying out each experiment, 1 × 106 U937 cells were 
seeded in a 25 mm2 culture flask and differentiated in a monolayer by 
adding Phorbol 12-myristate 13-acetate (PMA) at a final concentration 
of 50 nM for 48 h and then washed twice with 1 × phosphate buffered 
saline (1 × PBS), and fresh media added (Maia et al., 2007). 
P. falciparum 3D7 (obtained from MR4-ATCC) chloroquine-sensitive 
parasites were cultured with human red blood cells (RBCs) obtained 
from the Blood and Tissue Bank (Catalonia, Spain), after approval from 
Hospital Clínic of Barcelona’s Clinical Research Ethics Committee. 
Parasites were co-cultured with B + RBCs (3% hematocrit) in RPMI 
medium with 10% human AB + type serum, and kept at 37 ◦C in an 
atmosphere of 93% N2, 2% O2, and 5% CO2. In order to select ring stage 
parasites, a sorbitol synchronization protocol was followed, keeping 
infected erythrocytes at 37 ◦C for 10 min with 10 times its volume of 
sorbitol 5% (Trager and Jensen, 1976). 
The T. brucei brucei 427 strain was maintained in HMI-9 culture 
medium [Iscove’s modification of DMEM (IMDM; Cell Gro) supple-
mented with 10% FBS, 10%, Serum plus (SAFC), 0.05 mM Bath-
ocuproinesulfonate, 1.5 mM L-cysteine, 1 mM hypoxanthine, 0.2 mM 
β-mercaptoethanol, 0.16 mM thymidine 1 mM pyruvate)] and passages 
were performed twice weekly. 
CL strain T. cruzi overexpressing a tdTomato red fluorescent protein 
was used (Canavaci et al., 2010). Parasites were maintained in Vero cell 
cultures through weekly passage. Fibroblast-like kidney cells from Af-
rican green monkey (Vero cells, ECACC) were purchased from Sigma 
Aldrich (Ref 84113001). Vero cells were maintained in culture media 
[RPMI 1640 supplemented with 10% fetal bovine serum, gentamycin 
(25 μg/mL), Penicillin/Streptomycin (0.1 mg/mL), L-glutamine (2 mM), 
sodium pyruvate 1 mM), and 2-mercaptoethanol (50 μM)] at 37 ◦C and 
5% CO2. Passages were performed twice weekly. After 4–5 days of 
culture, trypomastigotes released from Vero cells were collected to carry 
out the drug screening assay. 
2.2. Drugs 
3BP (CAS N1113-59-3), DCA (CAS N 79-43-6), 2DG (CAS N 154-17- 
6), LND (CAS N 50264-69-2), MET (CAS N 1115-70-4), and SIR (CAS N 
53123-88-9) (Table 1) were purchased from Sigma-Aldrich and freshly 
prepared before use in the appropriate culture media. The following 
reference drugs were selected as positive controls: chloroquine (CQ) for 
P. falciparum, benznidazole (BZD) for T. cruzi, meglumine antimoniate 
(Glucantime®, Sanofi-Avensis) for L. infantum intracellular amastigotes, 
amphotericyn B (AmB) (Sigma-Aldrich) for L. infantum promastigotes, 
and suramin (SUR) for T. brucei in vitro experiments. 
2.3. Cytotoxicity to mammalian cells 
In order to test toxicity on human macrophages, 5 × 104 U937 
differentiated cells per well were seeded in 96-well microplates, and 
cultured with increasing concentrations of 3BP, DCA, 2DG, MET, LND, 
and SIR diluted in RU937 culture media. Each concentration was 
assayed in triplicate. The cells were kept at 37 ◦C in a 5% CO2 atmo-
sphere. Cell viability was determined 48 h later by the MTT assay. 
Briefly, Thiazolyl Blue Tetrazolium Bromide (MTT) was added to each 
well at a final concentration of 0.5 mg/mL. After 4 h of incubation in the 
dark, 100 μL of HCl 0.1 N in isopropanol +10% Triton X-100 was added 
to each well to solubilize the resulting formazan crystals, and then read 
at a wavelength of 570 nm (reference 690 nm). The Alamar Blue 
(Invitrogen) assay was performed in the case of 3BP, in order to avoid 
interferences (Ganapathy-Kanniappan et al., 2010). Alamar Blue was 
added in an amount equal to 10% of the culture volume and plates were 
kept in the incubator for 24 h. Absorbance was read at 570 nm and 
600 nm, and results were calculated following the manufacturer’s 
recommendations. 
For cytotoxicity assays on Vero cells, 1.7 × 104 cells were seeded in 
black, clear-bottom 96-well plates and incubated overnight at 37 ◦C and 
in 5% CO2. Serial dilutions of the drugs were added and incubated at 
37 ◦C and in 5% CO2 for 72 h. Alamar Blue (AbD Serotec) was then 
added and the measurements performed 6 h later as described above. 
In order to evaluate the compatibility of the selected drugs and 
erythrocytes, hemolysis was studied in vitro by direct spectrophotom-
etry. RBCs (3% hematocrit) were cultured in round-bottom 96-well 
plates and incubated for 48 h with serial dilutions of the studied com-
pounds in a humid atmosphere with concentrations of 5% CO2, 2% O2, 
and 93% N2. Each sample was assayed in duplicate, and a positive 
control for hemolysis was included by adding autoclaved distilled water 
to a well containing RBCs. The Harboe method was used to assess hae-
molysis (Harboe, 1959). 
2.4. Effect of bioenergetic modulators on L. infantum 
The killing effect of these drugs was assessed in vitro against the two 
stages of the biological cycle of Leishmania: motile promastigotes in the 
sand-fly vector and intracellular amastigotes in the host. 
2.4.1. Anti-L. infantum promastigotes drug test 
Promastigotes from a 4-day culture were seeded at 1 × 105 parasites 
per well in a 96-well microplate with increasing concentrations of drugs 
for 48 h at 26 ◦C. AmB at 0.25 μM was used as positive control. In order 
to determine parasite viability, the phosphatase activity assay was per-
formed. Briefly, parasites were completely lysed using a solution made 
of 1% Triton X-100 and 2.9% sodium citrate in distilled water. Then, 
5 mM of p-nitrophenyl phosphate was added to each well. In viable cells, 
p-nitrophenyl phosphate was hydrolyzed by intracellular acid phos-
phatases to p-nitrophenol. After 2 h of incubation at 37 ◦C, the reaction 
was stopped by adding 60 μL of NaOH 1 N to each well. Data were 
collected by reading the optic density at a wavelength of 405 nm (Yang 
et al., 1996). 
2.4.2. Drug test on L. infantum intra-macrophage amastigotes 
Cell line U397 was cultured in 25 mm2 flasks and differentiated as 
explained above. Metacyclic promastigotes (6 days’ culture) were added 
to the pre-washed differentiated cell culture at a parasite:cell ratio of 
10:1, and co-cultured for 24 h. They were then washed with 1 × PBS to 
discard non-internalized promastigotes. Infected macrophages were re- 
suspended in RU937 and incubated in 8 well chamber slides at a den-
sity of 5 × 104 with increasing, but non-toxic to human macrophages, 
concentrations of 3BP, DCA, 2DG, SIR, LND, and MET for 48 h. Meglu-
mine antimoniate at a concentration of 273 μM was used as positive 
control. Each concentration was tested in duplicate. Preparations were 
fixed with methanol and stained with Giemsa 11%. The numbers of 
infected macrophages and the intracellular parasites were recorded by 
direct microscopic count of 200 cells per sample. 
2.5. P. falciparum growth inhibition assay 
RBCs were cultured in RPMI and spiked P. falciparum ring infected 
erythrocytes to a final hematocrit of 3% and 0.8% infected blood cells. 
Cultures were then transferred to 96 microwell plates and exposed to 
increasing concentrations of 3BP, DCA, 2DG, MET, LND, and SIR pre-
pared in media culture. CQ (80 nM) was used as reference drug to 
achieve parasite growth inhibition values above 90% (>IC90). Each 
concentration was assayed in triplicate and kept at 37 ◦C in a 5% CO2, 
93% N2, and 2% O2 atmosphere. After 48 h, parasitemia was determined 
by fluorescence-assisted cell sorting [FACS] (BD LSRFortessa™ cell 
A. Martínez-Flórez et al.                                                                                                                                                                                                                      
International Journal for Parasitology: Drugs and Drug Resistance 14 (2020) 17–27
20
analyzer, Becton Dickinson), after staining infected RBCs with SYTO 11 
(Molecular Probes, Life Technologies). Non-infected RBCs and infected 
non-treated RBCs were used as controls. 
2.6. Screening of drugs against T. brucei 
Cultured parasites were collected and spun for 10 min at 900 g to 
eliminate supernatant and were then cultivated at 5 × 105 parasites per 
well in a 96-well white, sterile plate in warm medium with serial di-
lutions of the selected compounds. Suramin (SUR) at 100 μM was used as 
positive control. Each concentration was tested in triplicate. After 24 h, 
Alamar Blue (Sigma) was added as previously described, and plates were 
incubated at 37 ◦C for 4 h before fluorescence was read at excitation (Ex) 
530 nm and 590 nm emission (Em) wavelength. 
2.7. Drug test on intracellular amastigotes of T. cruzi 
Gamma-irradiated (2200 rad) Vero cells were plated in 96-well, 
black, clear-bottom plates at 3.6 × 104 cells per well and left overnight 
at 37 ◦C, in 5% CO2 atmosphere. Vero cells were then infected with 
3.6 × 105 trypomastigotes of the CL tdTomato strain of T. cruzi per well 
for 5 h at 37 ◦C and 5% of CO2. After infection, the plates were washed 
once with Hanks’ solution to eliminate extracellular parasites and 
cultured again in the presence of serial dilutions of the selected com-
pounds. Benznidazole was used as a positive control drug at a 
concentration of 2 μM. Each concentration was assayed in quadrupli-
cate. After 72 h, fluorescence was measured (Ex = 544 nm; 
Em = 612 nm). 
2.8. Data analysis 
In all cases, results were expressed as the percentage inhibition of 
parasite growth in relation to the infected but non-treated controls for 
each assay (100 − [(mean parasitemia treated/mean parasitemia con-
trol) × 100]). In case of Plasmodium viability assays, values were firstly 
standardized based on that obtained with CQ for eliminating technique- 
dependent variability (post-treatment presence of DNA debris in sam-
ples with death parasites). 
IC50 values were determined by using a sigmoidal dose-response 
with variable slope equation (Y = Bottom + ((Top - Bottom)/(1 + 10 
(LogIC50 - X) - Hill Slope))) (GraphPad Prism Software v5). 
3. Results 
3.1. Leishmanicidal activity of bioenergetic modulators on L. infantum 
promastigotes and intramacrophagic amastigotes 
The activity of DCA, 3BP, 2DG, LND, MET, and SIR on Leishmania 
promastigotes was assessed after culturing parasites with the drugs for 
48 h. Only 3BP and 2DG showed a slight parasite-killing effect at doses 
Fig. 1. Efficacy of DCA and 3BP on L. infantum-infected macrophages. Dose-response curves showing the inhibition of L. infantum intracellular amastigotes growth 
(1) and L. infantum-infected macrophages (2). The percentage inhibition was determined by comparing with untreated controls after 48 h of treatment with (A) DCA 
and (B) 3BP. Each point represents the mean ± standard error of the mean (SEM) obtained from three independent tests where each concentration was tested 
in duplicate. 
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of 37 μM and 0.2 mM, respectively, and did not reach the values ob-
tained by the control drug AmB (0.25 μM) (36% survival rate) (data not 
shown). SIR, DCA, MET, and LND did not detectably impair L. infantum 
promastigote survival. 
When these compounds were tested in an infection assay of L. 
infantum intra-macrophage amastigotes, an inhibitory, dose-dependent 
effect was observed in infected and treated cells with 3BP and DCA. 
The percentages of infected macrophages after 48 h of treatment with 
the highest, but non-cytotoxic doses of these compounds, were reduced 
by 74.4% for 25 mM of DCA and 48.4% for 75 μM of 3BP. Concurrently, 
the number of intracellular amastigotes decreased by 90.7% for DCA 
and 78.3% for 3BP, values 31.1% and 18.6% higher than those obtained 
with meglumine antimoniate at 273 μM, respectively (Fig. 1). Their 
parasite-killing activity is translated to IC50 values of 631.5 μM for DCA 
and 24.94 μM for 3BP (Table 2). The other tested drugs only showed a 
slight effect, and their anti-parasitic activity was lower than that pro-
duced by meglumine antimoniate (data not shown). SIR did not show 
any parasiticidal effect although a modest increase of the parasite 
burden and number of infected macrophages were observed at a con-
centration of 10 μM (data not shown). 
3.2. Antiplasmodial activity of bioenergetic modulators 
P. falciparum intraerythrocytic stages were sensitive in a dose- 
dependent manner to DCA, 2DG, SIR, and MET and reached growth 
inhibition values close to those obtained by CQ. IC50 values (Table 2) 
indicate P. falciparum is highly susceptible to SIR (IC50 = 2.50 μM) while 
other assayed compounds as DCA (IC50 = 5.39 mM), 2DG 
(IC50 = 4.19 mM), and MET (IC50 = 1.32 mM) needed higher concen-
trations to inhibit parasite growth. A slight effect on parasite growth 
inhibition was observed at high concentrations for 3BP. LND showed a 
peak of antimalarial activity at 300 μM (IC50 = 209.13 μM) (Fig. 2). 
3.3. Anti-T. brucei activity of bioenergetic modulators 
DCA and SIR achieved complete clearance of cultured T. brucei brucei 
parasites at 12.5 mM (IC50 = 1.24 mM) and 6.85 μM (IC50 = 2.14 μM) 
concentrations, respectively. Similar values were also obtained for LND 
(IC50 = 26.76 μM) and 3BP (IC50 = 76.57 μM), showing 97.7% and 
93.2% parasite-killing activity, respectively. MET only produced 57% 
parasite elimination at 20 mM (IC50 = 17.30 mM) (Table 2). No parasite- 
killing activity was detected for 2DG. SUR 100 μM was used as a control 
drug, inducing nearly complete parasite clearance (96%) (Fig. 3). 
3.4. Effect of bioenergetic modulators on T. cruzi amastigotes 
LND and 2DG produced the highest reduction in T. cruzi amastigote 
numbers, reaching inhibition values of 99.4% (IC50 = 82.41 μM) and 
89.3% (IC50 = 7.27 mM), respectively. DCA and MET also decreased 
parasite survival but did not reach the level of the positive control. DCA 
action required high concentrations (up to 100 mM) in order to reach the 
highest value of 74.1% (IC50 = 25.82 mM), while MET only produced 
mild inhibition with a maximum of 51.7% at 20 mM (IC50 = 18.48 mM) 
(Table 2). A sustained mild reduction in fluorescence was detected at 
higher concentrations, which may suggest a trypanosomastatic effect 
(Fig. 4). In contrast, 3BP and SIR did not show consistent anti-
trypanosomal activity (data not shown). 
4. Discussion 
The aim of this study was to demonstrate and compare the in vitro 
effectiveness of different bioenergetic modulators previously used in 
diagnostic and anticancer studies on L. infantum, P. falciparum, T. cruzi, 
and T. brucei. These drugs were selected because of their modulating 
activity on enzymatic pathways known to be related to ATP production, 
proliferation, and cell survival strategies. To the best of our knowledge, 
this is the first time that some of these bioenergetic modulators have 
been specifically used for this purpose. DCA has demonstrated a 
remarkable in vitro parasiticidal activity in models of highly replicative 
stages of L. infantum, P. falciparum, T. cruzi, and T. brucei. Moreover, 
although 2DG has been utilized several times to measure glucose uptake 
in different cellular models, this is the first time it has been specifically 
employed for a parasite-killing indication. It is also the first time that 
LND activity has been tested in L. infantum and P. falciparum in vitro 
models, and in the case of 3BP, additionally in a T. cruzi in vitro model. 
Although biguanides antiplasmodial properties are widely known, this is 
the first study where MET activity has been assayed in a L. infantum and 
T. brucei in vitro model. 
Our results show that bioenergetic modulators have greater efficacy 
on those parasites that are more dependent on glycolysis, as is the case 
for T. brucei and P. falciparum (Michels et al., 2006; Schalkwyk et al., 
2008; Salcedo-Sora et al., 2014). Apart from the specific efficacy of the 
compounds in the inhibition of target enzymes, such differential para-
siticidal activity profile of the studied compounds may be due to the 
contrasting life-condition adaptations and physiological particularities 
of each organism. Thus, whereas T. cruzi and Plasmodium spp. are hosted 
in the cytoplasm of the mammalian host cell during their asexual 
intracellular stage, and T. brucei prefers multiplying in the host blood-
stream thereby exploiting its glucose serum levels, Leishmania spp. show 
Table 2 
IC50 values obtained from selected drugs during protozoan parasites in vitro studies.  








L. infantum intracelular 
amastigotes 
L. infantum infected 
macrophages 
IC50 IC50 IC50 IC50 IC50 
3BP – – 7.66 ± 0.22 £ 10− 5 2.49 ± 0.23 × 10− 5 >7.50 × 10− 5 7.50 × 10− 5 to 
2.40 × 10− 8 
DCA 5.39 ± 0.67 × 10− 3 2.58 ± 0.59 × 10− 2 1.24 ± 0.05 × 10− 3 6.32 ± 1.63 × 10− 4 2.69 ± 1.58 £ 10− 3 2.50 × 10− 2 to 
1.00 × 10− 4 
2DG 4.19 ± 0.21 × 10− 3 7.27 ± 0.47 £ 10− 3 – – – 1.60 × 10− 2 to 
2.00 × 10− 3 
LND 2.09 ± 0.13 × 10− 4 8.24 ± 0.15 × 10− 5 2.68 ± 0.26 × 10− 5 – – 3.00 × 10− 4 to 
1.2 × 10− 6 
MET 1.32 ± 0.18 × 10− 3 1.85 ± 0.18 × 10− 2 1.73 ± 0.15 × 10− 2 – – 4.00 × 10− 2 to 
6.4 × 10− 6 
SIR 2.50 ± 0.47 × 10− 6 – 2.14 ± 0.11 £ 10− 6 – – 1.00 × 10− 5 to 
0.10 × 10− 6 
Abbreviations: IC50 values are given in molar (M) ± standard deviation. Acronyms: 3BP (3-bromopyruvic acid), DCA (dichloroacetic acid), 2DG (2-deoxy-D-glucose), 
LND (lonidamine), MET (metformin), and SIR (sirolimus). 
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Fig. 2. Growth inhibition of P. falciparum. Dose-dependent effect of (A) dichloroacetic acid, (B) sirolimus, (C) metformin, (D) lonidamine, and (E) 2-deoxy-D-glucose 
on P. falciparum in vitro assays. Data was obtained by flow cytometry and the inhibition of parasite growth was standardized with CQ-treated results and then 
calculated with respect to infected but untreated RBCs. Each concentration was tested in triplicate and data represent mean ± SEM of three independent experiments. 
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special metabolic features as a result of their adaptation to the low 
glucose concentration in PV (Naderer and McConville, 2008). Although 
glucose oxidation plays an important role in Leishmania spp. (McCon-
ville et al., 2015), these parasites were less susceptible to glycolysis in-
hibitors than other assayed parasites. The apparent lack of activity of 
these compounds may be due to their low access to the parasitophorus 
vacuole where Leishmania amastigotes reside. 
DCA is the only bioenergetic modulator we have found to have 
antiparasitic activity at the asexual replicative stages within the host of 
the three genera of parasites studied. It reduced the parasite burden of 
infected cells in trypanosomatids and the number of infected cells for L. 
infantum in a dose-dependent manner. The main target of DCA is 
Fig. 3. Dose-response curves of anti-trypanosomal activity on T. brucei cultured parasites. Fluorescence values, obtained after culturing parasites with (A) 
dichloroacetic acid, (B) sirolimus, (C) metformin, (D) lonidamine, and (E) 3-bromopyruvic acid, were compared to non-treated controls to indicate their T. brucei- 
killing activity. Suramin was used as a positive control. Each point represents the mean ± standard error of the mean (SEM) obtained from three independent tests 
where each concentration was tested in triplicate. 
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pyruvate dehydrogenase kinase (PDK) (Stacpoole et al., 1998). PDK 
inhibits the activity of pyruvate dehydrogenase complex (PDH) which 
regulates the entrance of pyruvate —the end-product of glycolysis— to 
the mitochondria and its transformation to acetyl-CoA to start the citric 
acid cycle. Thus, when DCA inhibits PDK it is redirecting pyruvate to 
mitochondria and restoring mitochondrial respiration. Genes encoding 
for PDK have been found in T. brucei, T. cruzi, and L. major (Parsons 
et al., 2005). However, bloodstream T. brucei is known to have an 
alternative mitochondrial oxidase non-dependent on pyruvate meta-
bolism, and therefore, PDK is not involved (Chaudhuri et al., 1998). This 
fact suggests there must be other possible targets of DCA still unknown 
in this stage of T. brucei. The high IC50 observed for DCA in T. cruzi may 
suggest that this is not an essential target at this stage, however low 
accessibility of the compound to the parasite enzyme and or its speci-
ficity may also be a cause for its reduced efficacy. No PDK genetic se-
quences have been identified in P. falciparum (Ward et al., 2004). 
However, our results show a dose-dependent inhibition of parasite 
growth by DCA on the intra-erythrocytic stage of P. falciparum, sug-
gesting additional effects of this compound on other essential steps for 
parasite survival in a non-host cell dependent manner due to the basic 
metabolism of erythrocytes. The ability of this compound to restore 
mitochondrial activity may also lead to a decrease of pyruvate avail-
ability for other biosynthetic pathways, such as alanine biosynthesis 
(Tielens and van Hellemond, 2009). The parasite-killing activity of this 
drug could, therefore, be enhanced by a lack of key proteins for parasite 
survival. Whilst several studies have shown the efficacy of DCA in 
rapidly reducing the concentration of lactic acidosis, a common 
complication of severe malaria strongly related to death in children 
(Agbenyega et al., 2003), this is the first time that its antiplasmodial 
activity has been demonstrated. 
In addition, DCA activity may also be boosted through actions trig-
gered in the host cell. Many protozoans such as Leishmania and Toxo-
plasma activate and stabilize HIF1A in the host cell (Wiley et al., 2010; 
Singh et al., 2012). HIF1A controls the cellular response to low oxygen 
stress inducing the transcription of genes related to the metabolic switch 
from oxidative phosphorylation to glycolytic profile, angiogenesis, and 
apoptosis inhibition (Semenza, 2012). Such a strategy may help these 
parasites to survive by taking advantage of the increase in macromole-
cules provided by glycolytic metabolism and the induced inhibition of 
host cell apoptosis. It has been recently described that the DCA 
anti-tumor effect also takes place by decreasing HIF1A activity in cancer 
cells (Sutendra et al., 2013). As a consequence, the observed DCA 
parasite burden reduction may be related to a decreased HIF1A activity 
and, in turn, the loss of the metabolic advantages that the host cell 
provides to its undesirable guests. 
We found that the glycolysis inhibitor 3BP showed antiparasitic ac-
tivity on T. brucei and L. infantum intracellular amastigotes, with po-
tential for VL and African trypanosomiasis treatment. Previous studies 
Fig. 4. Parasite-killing activity on T. cruzi intracellular amastigotes. The dose-dependent reduction in emitted fluorescence with respect to non-treated controls 
represents the parasite-killing power of (A) dichloroacetic acid, (B) lonidamine, (C) metformin, and (D) 2-deoxy-D-glucose. Each concentration was assayed in 
quadruplicate in three independent tests and mean values and SEM are represented in the figure. 
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have reported some activity on T. brucei, inhibiting motility and growth 
at 13.4 μM (Barnard et al., 1993), which corroborates our results. 
Nevertheless, we found no efficacy of 3BP against either T. cruzi or P. 
falciparum asexual replicative forms despite these parasites being also 
highly dependent on glycolysis. The main target of 3BP is GAPDH, an 
enzyme of the glycolytic pathway which, in the case of kinetoplastida, is 
localized mainly in the glycosomes. Some Leishmania species also have a 
cytosolic GAPDH isoenzyme shown to play a significant role in VL 
(Zhang et al., 2013). The efficacy we observed on Leishmania may 
therefore be due to the inhibition of both isoenzymes. A predictive 
model led to the conclusion that slight depletions of glycosomal GAPDH 
result in complete impairment of growth and ATP synthesis in L. 
infantum amastigotes (Subramanian et al., 2015), thus reinforcing the 
role of this enzyme for parasite-killing purposes. Furthermore, an in-
crease in GAPDH expression in Leishmania spp. has been related to a 
resistance to NO (Rios et al., 2015), a basic molecule for intracellular 
parasite clearance (Mauël et al., 1991). Blocking GAPDH with 3BP 
would avoid this resistance and allow parasite-killing. Despite 3BP 
apparently being safe in rodents, where only a reduction in body weight 
was recorded (Schaefer et al., 2012), 3BP could not be a therapeutic 
option because of its toxicity in humans (Barnard et al., 1993). However, 
its molecular target can still be considered for further research. 
2DG has been used as a substrate to measure glucose intake in many 
cell systems due to its condition as a mannose analog that cannot be 
further metabolized, and also in PET scanning for cancer diagnostic 
purposes. It blocks glycolysis because it cannot be further metabolized 
after phosphorylation by the first enzyme of the glycolysis pathway, 
hexokinase (HK) (Nirenberg and Hogg, 1958). HK isotypes are overex-
pressed in cancer cells and bound to the mitochondria, thus contributing 
to the maintenance of the Warburg effect (Bustamante and Pedersen, 
1977). LND inhibits HK1 mitochondrial-bounding in tumor cells (Paggi 
et al., 1988), and has been reported to also inhibit that of T. brucei 
(Chambers et al., 2008). The efficacy of LND on trypanosomatids has 
been described and tested on several species, including T. cruzi epi-
mastigotes (Turrens, 1986), T. brucei bloodstream and procyclic forms 
(Chambers et al., 2008) and L. mexicana promastigotes (Turrens and 
Cazzulo, 1987). We found an IC50 for T. cruzi amastigotes very close to 
that previously observed in epimastigotes (IC50 = 80 μM) (Turrens, 
1986) and even lower for BS forms of T.brucei in comparison to former 
authors (IC50 = 50 μM) (Chambers et al., 2008). In contrast, no effect 
was detected on L. infantum promastigotes. Results previously presented 
by other authors demonstrate that only a leishmaniostatic effect was 
observed for L. mexicana promastigotes at concentrations as high as 
0.5 mM (Turrens and Cazzulo, 1987). Both 2DG and LND showed anti-
plasmodial activity on P. falciparum. 2DG has been previously reported 
to interfere with glucose uptake in P. falciparum, with parasite glycol-
ysis, and with the synthesis of glycosylated macromolecules that play a 
key role in the intraerythrocytic stage development of trophozoites, 
therefore reducing their viability (Naik et al., 2000; Schalkwyk et al., 
2008). This is the first time LND has been used as an antiplasmodial 
compound. Because it resulted in 50% reduction of P. falciparum 
viability at concentrations of 209.13 μM, it emerges as a potential 
candidate for future malaria treatment. 
Whilst biguanides were initially developed as a potential treatments 
against malaria, MET’s ability to decrease blood sugar levels and the 
discovery of more powerful candidates to fight plasmodium, has resul-
ted in its employment for type II diabetes control. In this study, we have 
confirmed the previously described MET antiplasmodial activity 
(Sweeney et al., 2003) and report, for the first time, its efficacy against 
T. cruzi and T. brucei. MET is thought to block the mitochondrial 
respiratory-chain complex I. The presence of mitochondrial complex I in 
Trypanosomatida has been predicted, and all of its components identi-
fied, but electron transfer through complex I in T. brucei BSF has been 
demonstrated not essential for this parasite stage viability (Surve et al., 
2012). Thus, the mechanism why MET reduced T. brucei survival still 
remains unknown. Complex I inhibition by MET leads to metabolic and 
energetic stress, and activation of AMPK, thus causing down regulation 
of ATP-consuming processes and pushing the cell into a quiescent state 
(Fryer et al., 2002). However, if cells lack the ability to cope with en-
ergetic stress, as may be the case for tumor cells and highly glycolytic 
parasites, a metabolic crisis develops leading to death. In addition, the 
inhibition of the mitochondrial respiratory-chain complex I by MET in 
host cells reduces O2 consumption as the final acceptor of electrons in 
the electron transport chain. The subsequent redistribution of intracel-
lular O2 promotes hydroxylation of HIF1A by procollagen-proline 
dioxygenase (P4HA) and its destruction in the proteasome (Takiyama 
et al., 2011). As described above, HIF1A appears to be a key component 
for parasite survival, perhaps opening new avenues for anti-parasite 
therapeutic intervention. In the case of P. falciparum, there is an alter-
native NADH dehydrogenase in substitution of the classic complex I 
(Biagini et al., 2006). P. falciparum relies on its respiratory chain to 
support pyrimidine biosynthesis, and to maintain the essential mito-
chondrial membrane potential. Antiplasmodial activity of MET is 
explained by the disruption on metabolic pathways related to folates, 
responsible for purine and pyrimidine synthesis, for catabolism of 
several amino acids, and for glutathione synthesis, thus hindering 
parasite survival (Bridges et al., 2014). 
The mTOR route is a highly conserved pathway in eukaryotic or-
ganisms, that regulates the balance between catabolism and anabolism 
according to cellular needs by acting on ATP-generating routes, DNA 
transcription, synthesis of biological molecules, autophagy, and cell 
death (Sabatini and Laplante, 2012). In trypanosomatids, TORC2 
orthologue is the only TOR complex susceptible to SIR inhibition. 
TORC2 is involved in cytoskeletal actin reorganization, playing a key 
role during host cell invasion and parasite survival (Barquilla et al., 
2008). In our model, low concentrations of SIR were needed to induce T. 
brucei parasite depletion. The sensitivity of this parasite stage to SIR was 
already known as a previous study pointed to an even lower IC50 value 
than the one we obtained (IC50 = 152 nM) (Barquilla et al., 2008). 
However, this may be reflecting the different sensitivity of the different 
T. brucei strains used. Curiously enough, SIR did not affect the viability 
of the intracellular forms of the other trypanosomatids analysed.In 
contrast, an increase of parasite load was observed in the case of Leish-
mania. Similar results have been reported in other intravesicular para-
sites, such as different Leishmania species (Schaible et al., 1999; Pinheiro 
et al., 2009; Jaramillo et al., 2011) or even in P. berghei during its 
intrahepatic stage when the parasite inhabits non-acidified PV (Hanson 
et al., 2013). It has been suggested that mTOR inhibition by SIR triggers 
autophagy and other processes in the host cell, providing them with 
nutrients for their survival and parasite replication (Brunton et al., 
2013). Such processes in the host cell may provide a feasible explanation 
since autophagy has been reported to promote the generation and 
maturation of replicative vacuoles of other intracellular pathogens, such 
as Coxiella sp. (Gutierrez et al., 2005). Moreover, the mTOR route is 
related to the production of NO in innate immune cells (Weichhart et al., 
2008), thus impairing intracellular parasite clearance by blocking 
mTOR activity when SIR is administered. 
In case of the intraerythrocytic stages of P. falciparum, our results 
concur with previous studies, obtaining an IC50 around 2,5 μM (Bell 
et al., 1994; Yap et al., 2014). Erythrocytes have high avidity for SIR, 
therefore most of it reaching the bloodstream is sequestered in RBCs and 
bound to their immunophilin binding protein FKBP12 (Trepanier et al., 
1998). RBCs have an iron dependent mTOR pathway that regulates 
hemoglobin production and erythrogenesis. However, SIR has shown 
only modest effect on RBCs in contrast to other mTOR inhibitors 
responsible for anemia and the decrease in different blood cell pop-
ulations (Knight et al., 2014). Besides, whilst some authors have even 
indicated the expression of mTORC1 and C2 proteins in the proteome of 
mature erythrocytes, there is no evidence of functional proteins (Ales-
sandro et al., 2010). It may be assumed, therefore, that erythrocytes 
concentrate SIR, exposing the intracellular P. falciparum forms to high 
concentrations, and that the observed growth inhibitory effect relies 
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purely on the parasite-drug interaction. To date no Plasmodium ortho-
logues of mTOR have been found (van Dam et al., 2011). Nevertheless, 
SIR has been reported as developing its action by inhibiting the activity 
of the only FKBP described in P. falciparum (PfFKBP35), which is 
involved in protein folding and stabilizing, and is an essential chap-
erone, thus affecting parasite viability (Monaghan and Bell, 2005). 
All the concentrations used in this project were selected for being 
non-cytotoxic to the in vitro models of host cells for each parasite, which 
provides limited information since toxicity to other cell types or tissues 
cannot be discarded. However, some of these compounds have a long 
track record of in vitro and in vivo testing for other purposes or are even 
commercially available —as it is the case of MET, SIR—. Hence, there is 
a plethora of information about safety and adverse events of these 
compounds to facilitate the repositioning process. 
In conclusion, the activity of several compounds used in anti-cancer 
research were studied in different protozoan parasites in vitro models 
based in the principle that highly metabolically active and proliferation 
committed cells present an increased glycolytic metabolism and glucose 
uptake. The results show that metabolic pathways related to ATP and 
biomass production are promising targets, and drugs with proven effect 
on these routes are potential candidates for repurposing. This broad 
principle might offer an economic way to prevent a wide range of 
neglected parasitic diseases by simply repurposing of existing 
commercially-approved drugs or in advance stage of development to this 
new indication. However, more research has to be carried out as the 
underlying mechanisms of action of the assayed compounds on each 
parasite metabolism have to be further characterized. 
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